Clinical Trial

Excision BioTherapeutics Awarded a “Fierce 15” Biotech Company of 2024

Company Applying its Proprietary CRISPR Technology to Address Recurrent Infections in Herpes Simplex Keratitis (HSK)HSK is the Leading Cause of…

1 year ago

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company…

1 year ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

PDUFA Action Date for the Arimoclomol NDA is September 21, 2024CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics,…

1 year ago

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and…

1 year ago

Anivive Receives NIAID Contract Worth Up to $33M to Progress Valley Fever Vaccine

LONG BEACH, Calif., Aug. 2, 2024 /PRNewswire/ -- Anivive Lifesciences Inc, a One Health technology company today announced that the National…

1 year ago

Sensitech Completes Acquisition of Berlinger & Co. Monitoring Solutions Expanding Life Sciences Cold Chain Solutions

BEVERLY, Mass., Aug. 2, 2024 /PRNewswire/ -- Carrier Global Corporation, on behalf of its Sensitech business, a world leader in…

1 year ago

Chronic Prostatitis or Pelvic Pain Syndrome Treatment with Dr Allen’s Device Safely Prevents Prostate Enlargement (BPH)

Thermobalancing therapy with Dr Allen's Device treats chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) effectively and safely, helping to…

1 year ago

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01

Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to…

1 year ago

Distinguished experts join Verantos inflammatory bowel disease advisory panel

High-validity RWE company welcomes Cheifetz and Melmed PALO ALTO, Calif., Aug. 1, 2024 /PRNewswire/ -- Verantos, the global leader in high-validity…

1 year ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ETDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company…

1 year ago